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World Health Organization (WHO) defines natural
menopause as at least 12 consecutive months of
amenorrhea not due to physiologic and pathologic
causes. Statistics show that the mean age of natural
menopause is 51 years in industrialized nations,
compared to 48 years in poor and non-industrialized
nations.1 With the average life span extended to 70
years, most women will spend more than one third of
their life time beyond the menopausal transition. Be-
sides, the proportion of menopausal women is rising
since the aging population is expanding rapidly. Thus,
the health: of menopausal women becomes a prime
concern worldwide.
Menopause is a natural physiological phenomenon
resulting from primary ovarian failure secondary to
apoptosis or programmed cell death. Ovarian function
declines with age. The onset of menopause features the
decreasing production of estradiol, as well as
increasing levels of follicle-stimulating hormone* Corresponding author.
E-mail address: yuqimd@163.com (Q. Yu).
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women will experience a number of bothersome
symptoms, such as hot flashes, night sweats, vaginal
atrophy and dryness, dyspareunia, sleep disturbance,
and mood swings. Besides these, osteoporosis is the
most prevalent disease in menopausal women, and is
strongly associated with low quality of life and we
concentrate on postmenopausal osteoporosis in this
review.
Primary osteoporosis
Osteoporosis, a multifactorial systemic skeletal
disease, is characterized by low bone mineral density
(BMD) and micro-architectural deterioration of bone
tissue resulting in bone fragility.2 BMD measured by
dual X-ray absorptiometry is the gold standard to di-
agnose osteoporosis. According to WHO criteria,
osteoporosis is defined as the T-score of less or equal to
2.5 and osteopenia as the T-score between 1.0 and 2.5.
The femoral neck and lumbar spine are recommended
as the anatomic region of interest.3 BMD decreases
with age, thus primary osteoporosis mainly occurs in
women 10e15 years after menopause and elderly men
around 75e80 years old. With an expanding aging
population, osteoporosis and osteoporosis-related
fractures are fast becoming important public health
issues that are a considerable economic burden on
health service resources.Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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The achievement of peak bone mass is important to
bone health, and plays a vital part in preventing osteo-
porosis and subsequent fractures in later years. It is
reported that hip fractures could be reduced by 30%
with an increase in peak bone mass of 10%.2 Bone mass
accretion starts from childhood and continues into
adulthood, and peak bone mass can be achieved in the
mid-twenties for spine and hip while other bones, such
as the radius, reach a peak at age of 40 years. After that,
bone mass normally declines. By the age 70 years, bone
mass has decreased by 30e40%.4 The main determi-
nant of the peak bone mass is genetic factors. Studies
found several genetic variants which are related to bone
mass, including low-density lipoprotein receptor related
protein 5 (LRP5), osteoprotegerin (OPG), sclerostin
(SOST), oestrogen receptor 1, and the receptor activator
of NF-kB (RANK) pathway genes.5 It has been found
that hormone status regulates bone mass accretion,
especially that of estrogen. Other factors including
nutrition, smoking and exercise may also play a role in
the process of the peak bone mass accumulation.6,7
Healthy bone requires continuous remodeling which
is pivotal for bone density maintenance. It is estimated
that nearly 10% of the bone is updated by this process
every year.8 Osteoclasts (bone resorbing cells) and
osteoblasts (bone forming cells) are two kinds of cells
that essentially form the bone multi-cellular unit,
coordinating well to regular the balance of bone
resorption and bone formation. The normal bone
remodeling process consists of five phases: the resting
phase, the activation phase, the resorption phase, the
reversal phase, and the formation phase. Firstly, oste-
oclasts are recruited to the surface of the bone where
they generate an acidic micro-environment between
the cell and the surface of the bone, dissolving and
resorbing the mineral content of the bone. After that,
the osteoclasts undergo apoptosis and osteoblasts are
recruited to the bone surface and then deposit collagen
which is mineralized afterwards to form new bone.9
This process is regulated by several hormones,
including parathyroid hormone, calcitonin, 1,25(OH)2-
vitamin D3, and estrogen. Estrogen affects bone
through the following mechanisms: 1) lowering the
sensitivity of bone mass to PTH (parathyroid hor-
mone), thus reducing bone resorption, 2) increasing the
production of calcitonin, thus inhibiting bone resorp-
tion, 3) accelerating calcium resorption by the intes-
tine, 4) reducing the calcium excretion from the
kidney, and 5)estrogen can also have direct effects in
the bone since there are estrogen receptors.10At menopause the normal bone turnover cycle is
impaired by estrogen deficiency. This may be due to the
presence of estrogen receptors in osteoclast progenitor
cells and multi-nucleated osteoclasts. The osteoclastic
resorption activity increases while the osteoblastic ac-
tivity decreases. As a result, the amount of bone resor-
bed exceeds the amount deposited, which leads to a net
loss of bone. The increase of overall bone resorption is
due to a weakened inhibition effect due to the reduction
of available estrogen on both osteoclastogenesis and
osteoclast activity. The enhanced expression of cyto-
kines known to stimulate osteoclastogenesis, such as IL-
1, IL-6, and TNF, or enhanced expression of M-CSF
(macrophage colony-stimulating factor) and RANKL in
osteoblasts/stromal cells may also play an important
role. The stimulatory effect of estrogen on bone for-
mation is less-well-understood, but may be mediated by
estrogen-receptor-responsive elements on promoters for
genes involved in bone matrix biosynthesis, including
type I collagen, or cytokines believed to be important
for coupling of bone resorption and bone formation.8
There are two phases of bone loss in women: The first
occurs predominantly in trabecular bone and starting at
menopause. It results from estrogen deficiency, and
leads to a disproportionate increase in bone resorption as
compared with formation. This phase could be defined
as menopause related bone loss. After 4e8 years, the
second phase exhibits a persistent, slower loss of both
trabecular and cortical bone, and is mainly attributed to
reduced bone formation.11 This is age related bone loss,
which is the only phase that also happens in men.
During the menopausal transition period, the
average reduction in BMD is about 10%. Approxi-
mately half of women are losing bone even more
rapidly, perhaps as much as 10%e20% in those 5e6
years around menopause. About 25% of post-
menopausal women can be classified as fast bone
losers, and they could be discovered by the measure-
ment of bone loss and bone resorption markers.12
The epidemics of osteoporosis
The aging population is expanding at an unprece-
dented rate. This explosion in population will lead to a
greater number of individuals with osteoporosis. It is
estimated that the prevalenceof osteoporosis rises from1/
3 in people at age 50e60 tomore than50%ofpeople aged
over 80 years. By 2050, the global osteoporosis sufferers
will reach 6 million (including both males and females),
3/4 of who will reside in developing countries.13,14
The major health threat of osteoporosis is osteopo-
rotic fractures, which occur at a site associated with
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wrist, sometimes the humerus or ribs are also
involved), and it increases in incidence after the age of
50 years. Osteoporotic fractures take place in temporal
sequence, with the first sign being fractures of the
lower end of radius starting at age 50 years, followed
by vertebral fractures at age 60e75 years and hip
fractures beginning in the late 70s.9 Osteoporotic
fracture may lead to loss of mobility and autonomy, a
reduction of the quality of life and development of
serious complications such as pneumonia or thrombo-
embolic disease which poses a considerable health and
economic burden to public health. For example, during
the 1st year after hip fracture 20e30% of patients died,
with the cost amounting to about $21,000 in USD.15
The prevalence of osteoporosis and related fractures
are higher in postmenopausal women than in older men
since estrogen plays a key role in maintaining bone
health. The National Osteoporosis Foundation (NOF)
estimates there are 9.1 million women with osteopo-
rosis and an additional 26 million with low bone mass.
This far exceeds the estimated number of men with
osteoporosis, 2.8 million, and with low bone mass,
14.4 million.16 The fracture risk is also higher in
women than in men. The lifetime risk of fracture for a
60-year-old woman is close to 44%, nearly double the
risk for a man of the same age, which is 25%. In 2005,
there were nearly 1.45 million fractures in women
older than 50 years in the United States, compared with
594,000 fractures in men of the same age.17
Worldwide, the frequency of osteoporosis and oste-
oporotic fractures is also influenced by race and
ethnicity. Generally speaking, Caucasian and Asian
women are more susceptible to osteoporosis than black
women. In the United States, among women who suf-
fered from osteoporotic fractures, white women account
for the majority of all fractures, which is as high as 89%,
followed by blacks and Hispanics, both are 4%, and
other women 3%.18 Meantime, the lifetime risk of hip
fracture in the United States at age 50 years is 15.8%
and 6.0% in women and men, respectively, whereas in
Chinese women and men it is 2.4% and 1.9%, and in
Hispanic women and men 8.5% and 3.8%. Additionally,
it seems that hip fractures occur at an earlier age in
developing countries compared with western countries
since the peak age for hip fractures in India is in the 60s
compared to 80s in western countries.19 In a meta-
analysis evaluating the data on the epidemiology of
Chinese elderly people, the author found that the total
prevalence of osteoporosis at an age above 40 years in
China was 13.2%, and it is significantly higher among
females than males,14.2%vs. 11.8% (P < 0.05). Theprevalence of osteoporosis increases in both men and
women with aging, while it increases gradually in males
it increases significantly in females over 50 years old.20
The management of postmenopausal osteoporosis
As early as 1940s, Albright and Reifenstein found
that estrogen could prevent osteoporosis. In the 1960's,
the association between menopause and osteoporosis
was first identified and then estrogen treatment was
adopted to prevent bone loss. Nowadays, a large
number of studies have proven that estrogen is effec-
tive in the prevention of osteoporosis and hormone
therapy can still be considered a first line choice for
postmenopausal women.
Menopause Hormone Therapy (MHT) has long
been known to significantly increase BMD. In a meta-
analysis of 57 trials (both prevention and treatment
trials) which included about 10,000 women, the com-
bined results imply that on average the change in bone
density is significantly higher in the MHT group (both
opposed and unopposed estrogen) at all measurement
sites. After one year the MHT group showed an
average increase of bone mineral density at the lumbar
spine of 5.4%, and the forearm and femoral neck were
also increased by 3.0% and 2.5% respectively. After
two years of treatment, the percentage change in favor
of MHT increased by about 1.5% at all sites with an
increase by 6.8%, 4.5%, and 4.1% at the lumbar spine,
forearm, and femoral neck, respectively.9,21
TheHOPE trial recruited 822healthy postmenopausal
women 40e65 years old who were randomized to either
daily conjugated equine estrogen treatment with 0.3 mg,
0.45 mg or 0.625 mg with or without continuous daily
medroxy progesterone acetate at 1.5 mg or 2.5 mg. A
calcium supplement of 600 mg was given to all of the
participants including the placebo group. After two years
of treatment, compared to the placebo group, women
assigned to all of the active treatment groups had sig-
nificant gains from baseline (P < 0.001) in spine and hip
BMD, the difference being about 3e5% for spine BMD
and 1e3% for total hip BMD.22
MHT is also effective in preventing osteoporotic
fractures. In a meta-analysis of 22 randomized trials,
there was an overall 27% reduction favoring MHT
groups in non-vertebral fractures in a pooled analysis
(RR ¼ 0.73, 95% CI, 0.56e0.94, P ¼ 0.02). For hip
and wrist fractures alone, the effectiveness of MHT
appeared more striking (RR ¼ 0.60, 95% CI,
0.40e0.91, P ¼ 0.02).23
In the Women' s Health Initiative (WHI) study,
16,608 women were randomized to estrogen plus
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were randomized to estrogen (ET) or placebo. After
three years on ET and after two years on HT, the
fracture risk started to decrease. In the HT arm after 5.6
years, the risk of hip fractures was lowered by 33% and
the risk of all fractures was lowered by 24%. In the ET
trial of 10,739 women that were followed up for 7.1
years, there was a similar reduction in hip fractures of
35% and 29% in all fractures. In all, HT/ET results
showed reduced hip fractures by 35%.24 This trial
provides a strong support that hormone therapy is
effective in preventing osteoporotic fractures.
In a randomized trial investigating the effects of
tibolone on fractures,25 4538 women who are at risk for
fractures were assigned to a tibolone or placebo group.
During a median of 34 months of treatment, compared
with the placebo group, vertebral fractures in the tibo-
lone groupwere lower by 45%, (RR¼ 0.55, 95%CI, 0.41
to 0.74, P < 0.001), and nonvertebral fracture decreased
by 26% (RR ¼ 0.74, 95% CI 0.58 to 0.93, P ¼ 0.01).
It is worth mentioning that withdrawal of estrogen
results in rapid bone loss and within one year most of
the previous increased BMD accumulated over 3e4
years has disappeared. In a randomized study, which
included early post-menopausal women who age 55
years, MHT increased BMD by 5%e6%. However,
four years after treatment was stopped there was a
rapid decrease in spine BMD by 7% in the MHT
group. Another similar analysis showed that within two
years hip fractures increased by 50% and after five
years by 77%.26 It is recommended therefore that
women who discontinue MHT should select other
therapies to prevent osteoporosis.
The window of opportunity hypothesis
There is ceaseless debate about MHT since it may
relate to breast cancer, coronary heart disease (CHD),
strokes and thromboembolism.27,28 To prevent post-
menopausal osteoporosis, how can we weigh the risk/
benefit and when should we start menopause hormone
therapy? The window of opportunity hypothesis
emerges as an answer and has become accepted among
specialists from various countries today.
Cumulated data from studies concerning MHT
demonstrate two populations of postmenopausal women
who response differently to MHT. The diversified
response to MHT is based on age or years post-
menopausal. Specifically, when MHT is started in
women less than 60 years old and/or less than 10 years
postmenopausal, the CHD events and overall mortality
are decreased, and the overall benefits outweigh risks.Contrarily, whenMHT is started in women older than 60
years old and/or longer than 10 years after menopause,
there is a null effect and sometimes even an adverse
effect.27 That is the window of opportunity hypothesis.
The hypothesis is further validated by data published
recently from the DOPS study,28 which suggests that
MHT can reduce cardiovascular endpoints in women if
started shortly after menopause, which happens to be the
period of fast bone loss. Thus, the timing hypothesis
should be kept in mind when we are prescribing hor-
mones to prevent postmenopausal osteoporosis. As we
discussed in previous paragraphs, bone resorption has
been proven to be fastest in the first 3e4 years after
menopause, and it is reasonable to start hormone therapy
early after menopause. During this period of time, the
response to treatment can be the highest since stopping
resorption leads to instant filling in of the resorption or
remodeling space and increases bone formation and re-
sults in a greater increase in BMD.
The North American Menopause Society guidelines
suggest that as long as the lowest effective dose of MHT
is used, extending treatment for an individual woman's
treatment goals are acceptable when the benefits of
menopause symptom relief outweigh potential risks and
for further prevention of osteoporotic fracture or pres-
ervation of bone mass in women with an established
reduction in bone mass other therapies are not suitable.9
Determination of the lowest effective dose of MHT
should be based on vasomotor symptom relief.9
The Chinese menopause guidelines suggest that
menopause hormone therapy is recommended for
women who are at risk of osteoporotic fractures and
who are younger than 60 years old; while for those
who are older than 60 years, menopause hormone
therapy is not recommended if it is intended only for
the prevention of osteoporotic fractures.29 MHT should
be individualized in administration and dose, and
benefits/risks should be carefully weighed during the
treatment. To prevent osteoporosis, the lowest effective
dose of MHT should be used and there are fewer side
effects in transdermal preparations than with oral
medicines. Bone loss will recur after stopping hormone
therapy. For those who are at risk of osteoporotic
fractures, other protective drugs should be taken.29
What can we do for women greater than 60 years old
and/or greater than 10 years postmenopausal if they wish
to prevent osteoporosis? Other pharmacological in-
terventions including bisphosphonates, selected estrogen
receptor modulators (SERM), recombinant human para-
thyroid hormone, and denosumab are also effective.
Calcium and vitamin D should be taken as basic nutri-
tional supplements. Adjustment of lifestyle such as
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tegies for prevention of falls can also play a vital role.30
Summary
Being a systemic skeletal disease, osteoporosis be-
comes an important public health and financial issue that
is associated with increased mortality and morbidity.
Postmenopausal women are susceptible to primary
osteoporosis since osteoporosis is closely related to es-
trogen deficiency. During the menopausal transition
period, the drop of estrogen leads to more bone resorp-
tion than formation, resulting in osteoporosis. Themajor
health threat of osteoporosis is osteoporotic fractures.
The prevalence of osteoporosis and related fractures are
higher in postmenopausal women than in older men and
is influenced by ethnicity. Since low estrogen levels are
the main cause of postmenopausal osteoporosis, meno-
pause hormone therapy is considered as the first line
choice for prevention of osteoporosis and its effective-
ness has been demonstrated by various studies. How-
ever, hormone therapy is recommended for women who
are less than 60 years old and/or less than 10 years post-
menopausal. For those who are greater than 60 years old
and/or greater than 10 years postmenopausal, meno-
pause hormone therapy is not appropriate and other
medicines should be considered.
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